Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 271 Cr.
- Current Price ₹ 224
- High / Low ₹ 282 / 87.0
- Stock P/E 8.47
- Book Value ₹ 126
- Dividend Yield 0.00 %
- ROCE 27.7 %
- ROE 21.5 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 38.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 87 | 131 | 132 | 203 | 215 | 317 | |
| Sales growth | +51% | +0% | +54% | +6% | +64% | |
| 80 | 120 | 111 | 170 | 187 | 274 | |
| Operating Profit | 7 | 11 | 21 | 33 | 28 | 43 |
| OPM % | 8% | 8% | 16% | 16% | 13% | 14% |
| 0 | 0 | 1 | 2 | 1 | 2 | |
| Interest | 0 | 1 | 1 | 2 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit before tax | 7 | 11 | 20 | 32 | 27 | 43 |
| Tax % | 25% | 27% | 27% | 24% | 27% | |
| 5 | 8 | 15 | 25 | 20 | 32 | |
| EPS in Rs | 5.77 | 8.06 | 15.28 | 25.82 | 16.25 | 26.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 37% |
| TTM: | 68% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 38% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 | 12 |
| Reserves | 5 | 13 | 28 | 44 | 118 | 140 |
| 6 | 11 | 13 | 17 | 5 | 22 | |
| 12 | 12 | 12 | 16 | 22 | 44 | |
| Total Liabilities | 25 | 37 | 54 | 86 | 157 | 219 |
| 1 | 6 | 5 | 9 | 8 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 5 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 78 | 144 | 201 | |
| Total Assets | 25 | 37 | 54 | 86 | 157 | 219 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -6 | 0 | -0 | 4 | -3 | |
| -1 | -5 | -0 | -4 | -5 | |
| 7 | 5 | 0 | 3 | 43 | |
| Net Cash Flow | -0 | 0 | -0 | 3 | 36 |
| Free Cash Flow | -7 | -5 | -0 | -0 | -8 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -85% | 34% | 24% | 30% | 18% |
Ratios
Consolidated / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 83 | 85 |
| Inventory Days | 9 | 25 | 27 | 50 | 71 |
| Days Payable | 41 | 34 | 33 | 26 | 38 |
| Cash Conversion Cycle | 49 | 53 | 81 | 107 | 119 |
| Working Capital Days | 28 | 25 | 66 | 75 | 106 |
| ROCE % | 58% | 63% | 61% | 28% |
Insights
In beta| Mar 2024 | Sep 2025 | |
|---|---|---|
| Amino Acids Revenue Share % ・Standalone data |
|
|
| Sports Nutrition Revenue Share % ・Standalone data |
||
| Blending Capacity MT/Day |
||
| Customer Count Count |
||
| Grinding Capacity MT/Day |
||
| Number of Ingredients Count |
||
| Order Book INR Lakhs |
||
| Warehouse Capacity sq.ft |
||
Extracted by Screener AI
Documents
Announcements
- Financial Results For The Half Year Ended 30Th September 2026.
-
Regulation 32 Statement For The Half Year Ended 30Th September 2026.
- Chemkart reports no deviation in IPO proceeds use for half year ended 30 September 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation on Financial Results for the Half Year ended 30th September 2026.
-
Board Meeting Outcome for Dated 30Th October 2026.
- Board approved H1 FY27 unaudited results on 30 Oct 2026; standalone revenue Rs 20,447 lakh, PAT Rs 2,291 lakh.
-
Announcement under Regulation 30 (LODR)-Acquisition
- Chemkart invested Rs. 97.90 lakh in subsidiary Easy Raw Materials via rights issue on 27 Oct 2026.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.